https://register.epo.org/application?number=EP09706122
New Hope for Nerve Damage Patients as AstraZeneca/Ionis’ Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
Friday, FDA approved AstraZeneca
Related Posts
Sermonix Pharmaceuticals’ Lasofoxifene, Will Be Evaluated In A New Study Arm Of The Ongoing I-SPY Endocrine Program Sponsored By Quantum Leap Healthcare Collaborative, In Newly Diagnosed ER+ Invasive Cancer, Lasofoxifene Was In-Licensed From Ligand Pha…
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly
B. Riley Securities Maintains Buy on City Office REIT, Lowers Price Target to $12
B. Riley Securities analyst Craig Kucera maintains City Office REIT (NYSE:CIO) with a Buy and lowers the price target from $14 to $12.
Europe Approves Biogen’s Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.